Your institution may have access to this item. Find your institution then sign in to continue.
Title
Eligibility, compliance and persistence of sequential therapy with aromatase inhibitors following 2-3 years of tamoxifen in endocrine adjuvant breast cancer therapy.
Authors
Kilic, Nerbil; Myrick, Mary Elizabeth; Schmid, Seraina Margaretha; Gueth, Uwe
Abstract
This study evaluated the eligibility, compliance and persistence of sequential therapy, i.e. a switch to an aromatase inhibitor (AI) following 2-3 years of tamoxifen, in adjuvant endocrine breast cancer (BC) treatment.